Home/Investors/MPM Capital

MPM Capital

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$906.3M

Focus Areas

5

Top Stage

Phase 1/2

Investment Focus

Autoimmune Diseases Immunology Neuromuscular Disorders Metabolic Diseases Genetic Disorders

Portfolio Companies

Company	Stage	Valuation	Focus
Kyverna Therapeutics	Phase 1/2	$473.3M	Autoimmune Diseases, Immunology
Entrada Therapeutics	Phase 1/2	$433.0M	Neuromuscular Disorders, Metabolic Diseases

Frequent Co-Investors

Atlas Venture1 shared Vertex Pharmaceuticals1 shared Gilead Sciences1 shared Westlake Village BioPartners1 shared Kleiner Perkins1 shared Vida Ventures1 shared GordonMD1 shared 5AM Ventures1 shared